期刊
CANCER DRUG RESISTANCE
卷 4, 期 4, 页码 888-902出版社
OAE PUBLISHING INC
DOI: 10.20517/cdr.2021.44
关键词
Histone deacetylase; bortezomib resistance; selective HDAC inhibitors; HDAC6; HDAC7
类别
资金
- Karus Pharmaceuticals
- Novartis Pharmaceuticals
- National Cancer Institute [R01 CA184464, R01 CA194264]
- Leukemia & Lymphoma Society Specialized Center of Research [SCOR-12206-17]
- Dr. Miriam and Sheldon G. Adelson Research Foundation
This study investigated the expression of HDAC family members in bortezomib sensitive vs. resistant myeloma cell lines, with findings showing differential expression of HDAC6 and HDAC7 in these cells. Panobinostat was effective in inducing cell death and modulating HDAC expression in resistant cells. Inhibition of HDAC7 suppressed cell growth, while pharmacological inhibition of HDAC6 enhanced cell death induced by panobinostat, indicating distinct roles for these enzymes in bortezomib resistance.
Aim: Multiple myeloma (MM) is a hematological malignancy of antibody-producing mature B cells or plasma cells. The proteasome inhibitor, bortezomib, was the first-in-class compound to be FDA approved for MM and is frequently utilized in induction therapy. However, bortezomib refractory disease is a major clinical concern, and the efficacy of the pan-histone deacetylase inhibitor (HDACi), panobinostat, in bortezomib refractory disease indicates that HDAC targeting is a viable strategy. Here, we utilized isogenic bortezomib resistant models to profile HDAC expression and define baseline and HDACi-induced expression patterns of individual HDAC family members in sensitive vs. resistant cells to better understanding the potential for targeting these enzymes. Methods: Gene expression of HDAC family members in two sets of isogenic bortezomib sensitive or resistant myeloma cell lines was examined. These cell lines were subsequently treated with HDAC inhibitors: panobinostat or vorinostat, and HDAC expression was evaluated. CRISPR/Cas9 knockdown and pharmacological inhibition of specific HDAC family members were conducted. Results: Interestingly, HDAC6 and HDAC7 were significantly upregulated and downregulated, respectively, in bortezomib-resistant cells. Panobinostat was effective at inducing cell death in these lines and modulated HDAC expression in cell lines and patient samples. Knockdown of HDAC7 inhibited cell growth while pharmacologically inhibiting HDAC6 augmented cell death by panobinostat. Conclusion: Our data revealed heterogeneous expression of individual HDACs in bortezomib sensitive vs. resistant isogenic cell lines and patient samples treated with panobinostat. Cumulatively our findings highlight distinct roles for HDAC6 and HDAC7 in regulating cell death in the context of bortezomib resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据